Therapeutic modulators of STAT signalling for human diseases

被引：369

作者：

Miklossy, Gabriella ^{[1
,2
]}

Hilliard, Tyvette S. ^{[1
,2
]}

Turkson, James ^{[1
,2
]}

机构：

[1] Univ Hawaii, Ctr Canc, Canc Biol Program, Honolulu, HI 96813 USA

[2] Univ Hawaii, Ctr Canc, Nat Prod & Expt Therapeut Program, Honolulu, HI 96813 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2013年 / 12卷 / 08期

关键词：

HUMAN MULTIPLE-MYELOMA; HUMAN HEPATOCELLULAR-CARCINOMA; SMALL-MOLECULE INHIBITOR; DNA-BINDING ACTIVITY; SELECTIVELY INDUCES APOPTOSIS; GROWTH-SUPPRESSIVE ACTIVITY; TYROSINE-PHOSPHATASE SHP-1; LUNG-CANCER CELLS; NF-KAPPA-B; TRANSCRIPTION;

D O I：

10.1038/nrd4088

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The signal transducer and activator of transcription (STAT) proteins have important roles in biological processes. The abnormal activation of STAT signalling pathways is also implicated in many human diseases, including cancer, autoimmune diseases, rheumatoid arthritis, asthma and diabetes. Over a decade has passed since the first inhibitor of a STAT protein was reported and efforts to discover modulators of STAT signalling as therapeutics continue. This Review discusses the outcomes of the ongoing drug discovery research endeavours against STAT proteins, provides perspectives on new directions for accelerating the discovery of drug candidates, and highlights the noteworthy candidate therapeutics that have progressed to clinical trials.

引用

页码：611 / 629

页数：19

共 207 条

[1]

Adámková L, 2007, FOLIA BIOL-PRAGUE, V53, P1

[2] Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development [J].